Bio-Rad Laboratories, Inc.
NYSE:BIOMedical - Devices
-$0.65 today
- Market cap
- $9.95B
- Beta
- 1.08
- P/E (TTM)
- 45.4
- EPS (TTM)
- $6.26
Volume 0.46M
Average 0.38M
BIO Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Bio-Rad Laboratories, Inc.NYSE: BIO
Gross Profit · Q2 FY2026 · quarter ended Jun 2026
Gross profit grows in line with its trailing trend
Q2 FY2026 gross profit of $345.8M rose 0.1% year over year, ahead of the -0.4% change in trailing-twelve-month gross profit. Sequentially, it rose 11.8% from the prior quarter. Over 3 fiscal years it compounded at -5.0% a year.
Context
- Gross profit amounted to 52.0% of revenue in FY2025, down 1.7 pp from a year earlier.
- Gross profit increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +0.1% holds above the trailing-twelve-month pace of -0.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 1.34B USD
- Year-over-year change
- -2.6%
- 4-year CAGR
- -4.8%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.34B | -2.6% |
| FY2024 | 2024-12-31 | 1.38B | -3.4% |
| FY2023 | 2023-12-31 | 1.43B | -9.0% |
| FY2022 | 2022-12-31 | 1.57B | -4.3% |
| FY2021 | 2021-12-31 | 1.64B | — |
Gross Profit vs competitors
How BIO compares with its peers on the latest reported figures
- BIO's LTM Jun 2026 gross profit of $1.34B is the 5th highest of the 11 companies compared; the peer median is $604.19M.
- Its year-over-year change of -0.4% is the 9th highest of 11, against a peer median of +1.2%.
- Gross profit amounts to 51.9% of revenue for BIO, versus a peer median of 47.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $19.62B | +10.8% | -1.4% | 41.4% | |
| LTM Sep 2026 | $15.01B | +0.8% | -2.6% | 58.6% | |
| LTM Jun 2026 | $1.63B | -1.6% | +6.5% | 46.7% | |
| LTM Jul 2026 | $1.52B | +0.3% | -4.9% | 52.1% | |
| LTM Jun 2026 | $1.34B | -0.4% | -5.0% | 51.9% | |
| LTM Sep 2026 | $807.58M | +1.5% | +1.3% | 65.8% | |
| LTM Jun 2026 | $400.8M | +34.4% | -8.6% | 51.1% | |
| LTM Sep 2026 | $274.96M | +0.1% | +5.6% | 44.2% | |
| LTM Jun 2026 | $72.25M | +15.0% | -64.0% | 34.6% | |
| LTM Mar 2026 | $59.34M | +140.9% | +1.1% | 37.1% | |
| LTM Mar 2026 | $41.66M | -37.4% | +4.7% | 48.3% | |
| Peer median (excluding BIO) | $604.19M | +1.2% | -0.1% | 47.5% | |
Competitors are the stored peer set for BIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.92B | 2.8B | 2.67B | 2.57B | 2.58B |
| Cost of Revenue | 1.28B | 1.23B | 1.24B | 1.19B | 1.24B |
| Gross Profit | 1.64B | 1.57B | 1.43B | 1.38B | 1.34B |
| Gross Margin | 56.1% | 55.9% | 53.4% | 53.7% | 52.0% |
| Research & Development | 260.64M | 256.89M | 247.43M | 295.9M | 256.9M |
| Selling, General & Admin | 877.12M | 827.83M | 841.7M | 814M | 819.9M |
| Operating Expenses | 1.14B | 1.08B | 1.09B | 1.11B | 1.08B |
| Depreciation & Amortization | 137.6M | 137.3M | 145.9M | 151.6M | 165.4M |
| EBITDA | 5.59B | (4.53B) | (654.8M) | (2.14B) | 1.21B |
| EBITDA Margin | 191.2% | -161.6% | -24.5% | -83.5% | 46.8% |
| Operating Income | 500.34M | 482.62M | 337.8M | 269M | 270.5M |
| Operating Margin | 17.1% | 17.2% | 12.6% | 10.5% | 10.5% |
| Interest Income | 18.9M | 58M | 100.9M | 82M | 95.5M |
| Interest Expense | 1.55M | 38.11M | 49.44M | 48.9M | 49M |
| Other Income / Expenses | 4.95B | (5.19B) | (1.19B) | (2.61B) | 725M |
| Income Before Tax | 5.45B | (4.7B) | (850.1M) | (2.34B) | 995.5M |
| Pre-Tax Margin | 186.4% | -167.9% | -31.8% | -91.3% | 38.5% |
| Income Tax Expense | 1.19B | (1.08B) | (212.78M) | (498.3M) | 235.6M |
| Net Income | 4.25B | (3.63B) | (637.32M) | (1.84B) | 759.9M |
| Net Margin | 145.6% | -129.5% | -23.9% | -71.9% | 29.4% |
| EPS (Basic) | 142.61 | (121.79) | (21.82) | (65.36) | 27.87 |
| EPS (Diluted) | 140.83 | (121.79) | (21.82) | (65.36) | 27.87 |
| Weighted Avg Shares | 29.83M | 29.79M | 29.21M | 28.21M | 27.26M |
| Weighted Avg Shares (Diluted) | 30.21M | 29.79M | 29.21M | 28.21M | 27.28M |
Bio-Rad Laboratories, Inc.
NYSE:BIO
Intrinsic Alpha fair value
Locked
Current Price
$370.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.